Literature DB >> 16686372

Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using Atpase activity assays.

Cindy Q Xia1, Guangqing Xiao, Ning Liu, Satish Pimprale, Lisa Fox, Chris J Patten, Charles L Crespi, Gerald Miwa, Liang-Shang Gan.   

Abstract

P-glycoprotein (P-gp) is a transmembrane efflux transporter which possesses many important functions in drug absorption, disposition, metabolism, and toxicity. The ultimate goal of investigating drug interactions between P-gp and drug molecules in early drug discovery is to understand the contribution of P-gp to the pharmacokinetic and pharmacodynamic properties of drug candidates and to project drug-drug interaction (DDI) potentials in humans. Understanding species differences in P-gp activities further helps the prediction of P-gp-mediated drug disposition and DDI in humans from preclinical pharmacokinetics data. The objective of the present study is to investigate the species difference in P-gp activities, via P-gp ATPase assays, using rhesus monkey Mdr1, beagle dog Mdr1, and human MDR1 expressed insect cell membranes. Twenty-one compounds with diverse chemical structures and different P-gp binding sites were chosen for the ATPase assays. P-gp ATPase binding affinities (alphaKa) and fold increases in P-gp ATPase activities (beta) of P-gp substrates were determined. Consistent with the gene and amino acid similarity, the binding affinities of test compounds to rhesus monkey P-gp were much closer to those of human P-gp than beagle dog P-gp. This is the first study which investigates the ligand affinities of P-gp from three different species. The result of this study provides an example of how to use membrane P-gp ATPase assays to evaluate interspecies P-gp differences.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16686372     DOI: 10.1021/mp050034j

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  14 in total

Review 1.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

2.  Membrane Assays to Characterize Interaction of Drugs with ABCB1.

Authors:  Zsolt Fekete; Zsuzsanna Rajnai; Tünde Nagy; Katalin Tauberné Jakab; Anita Kurunczi; Katalin Gémes; Krisztina Herédi-Szabó; Ferenc Fülöp; Gábor K Tóth; Maciej Czerwinski; Greg Loewen; Peter Krajcsi
Journal:  J Membr Biol       Date:  2015-04-30       Impact factor: 1.843

Review 3.  Use of in vivo animal models to assess pharmacokinetic drug-drug interactions.

Authors:  Cuyue Tang; Thomayant Prueksaritanont
Journal:  Pharm Res       Date:  2010-04-29       Impact factor: 4.200

Review 4.  Challenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier.

Authors:  Noora Sjöstedt; Hanna Kortejärvi; Heidi Kidron; Kati-Sisko Vellonen; Arto Urtti; Marjo Yliperttula
Journal:  Pharm Res       Date:  2014-01       Impact factor: 4.200

Review 5.  A Critical Overview of the Biological Effects of Excipients (Part I): Impact on Gastrointestinal Absorption.

Authors:  Marilyn N Martinez; Balint Sinko; Fang Wu; Talia Flanagan; Enikő Borbás; Eleftheria Tsakalozou; Kathleen M Giacomini
Journal:  AAPS J       Date:  2022-05-02       Impact factor: 4.009

Review 6.  Advancement of structure-activity relationship of multidrug resistance-associated protein 2 interactions.

Authors:  Li Xing; Yiding Hu; Yurong Lai
Journal:  AAPS J       Date:  2009-06-03       Impact factor: 4.009

7.  Pregnancy does not increase CYP3A or P-glycoprotein activity in the non-human primate, Macaca nemestrina.

Authors:  Huixia Zhang; Xiaohui Wu; Suresh Babu Naraharisetti; Francisco Chung; Dale Whittington; Ahmad Mirfazaelian; Jashvant D Unadkat
Journal:  J Pharmacol Exp Ther       Date:  2009-05-28       Impact factor: 4.030

8.  Human-Mouse Chimeras with Normal Expression and Function Reveal That Major Domain Swapping Is Tolerated by P-Glycoprotein (ABCB1).

Authors:  Kristen M Pluchino; Matthew D Hall; Janna K Moen; Eduardo E Chufan; Patricia A Fetsch; Suneet Shukla; Deborah R Gill; Stephen C Hyde; Di Xia; Suresh V Ambudkar; Michael M Gottesman
Journal:  Biochemistry       Date:  2016-02-10       Impact factor: 3.162

9.  A Large Impact of Obesity on the Disposition of Ivermectin, Moxidectin and Eprinomectin in a Canine Model: Relevance for COVID-19 Patients.

Authors:  Alain Bousquet-Mélou; Anne Lespine; Jean-François Sutra; Isabelle Bargues; Pierre-Louis Toutain
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

10.  Differences in P-glycoprotein activity in human and rodent blood-brain barrier assessed by mechanistic modelling.

Authors:  Laurens F M Verscheijden; Jan B Koenderink; Saskia N de Wildt; Frans G M Russel
Journal:  Arch Toxicol       Date:  2021-07-15       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.